ResultsIQ › Latest results › Amrutanjan Health Care Limited
Amrutanjan Health Care Limited Q2 FY27 results deck summary
NSE: AMRUTANJAN · BSE: 590006
Results deck of 3 Nov 2026, summarised by AI from the filing.
Q2 FY27 net sales rose 14.85% to ₹135.18 cr with operating margin up 200 bps, as management guides 12-15% revenue growth for the year.
Key takeaways
- Q2 sales Q2 FY27 net sales were ₹135.18 cr (Q2 FY26: ₹117.70 cr, growth 14.85%), with PAT of ₹17.28 cr (growth 20.25%).
- Revenue guidance Management guides revenue growth of 12-15% for the year and aims to sustain a 12% operating profit margin.
- Margin recovery Q2 operating margins expanded by 200 basis points, with average gross margin at 41% vs 30-32% historical averages.
- Input inflation Packaging prices reached 1.5x last year levels and pulp prices are seen up 20%, projected to cut enterprise gross margin by 200 bps for the year.
Amrutanjan Health Care Limited Q2 FY27 results
As filed: Revenue ₹135 cr (+15% year on year), EBITDA ₹23.6 cr (+39% year on year), PAT ₹17.3 cr (+23% year on year), EBITDA margin 17.5% (+306 bps).
The Q2 FY27 score, against the company's own trend, is for premium members.
Earlier results and the share price after them
- Q1 FY27: Revenue ₹103 cr (+10% year on year), EBITDA ₹6.3 cr (−31% year on year), PAT ₹4.4 cr (−26% year on year), EBITDA margin 6.1% (−350 bps). Score 23 of 100, Below trend. Revenue growth was in line with the company's own trend; EBITDA and profit before exceptional items growth were well below it. EBITDA margin fell 350 bps year on year. Other income 63% of PBT. Revenue fell 31% from last quarter. Share price after the results: −7.6% in 30 days (Nifty 500: −3.1%).
- Q4 FY26: Revenue ₹150 cr (+11% year on year), EBITDA ₹25.6 cr (+42% year on year), PAT ₹16.2 cr (+36% year on year), EBITDA margin 17.1% (+373 bps). Score 64 of 100, In line with trend. Revenue and EBITDA growth were in line with the company's own trend; profit before exceptional items growth was above it. EBITDA margin rose 373 bps year on year. Share price after the results: +0.6% in 28 days (Nifty 500: −2.8%).
- Q3 FY26: Revenue ₹141 cr (+15% year on year), EBITDA ₹25.2 cr (+5% year on year), PAT ₹19.5 cr (+2% year on year), EBITDA margin 17.8% (−167 bps). Score 41 of 100, In line with trend. Revenue growth was above the company's own trend; EBITDA and profit growth were below it. EBITDA margin fell 167 bps year on year. Share price after the results: −2.1% in 30 days (Nifty 500: −3.2%).
- Q2 FY26: Revenue ₹118 cr (+7% year on year), EBITDA ₹17.0 cr (+21% year on year), PAT ₹14.0 cr (+17% year on year), EBITDA margin 14.4% (+168 bps). Score 40 of 100, In line with trend. Revenue and EBITDA growth were below the company's own trend; profit growth was in line with it. EBITDA margin rose 168 bps year on year. Revenue rose ₹8.0 cr on a year ago, against ₹11.0 cr the year before. Share price after the results: −7.1% in 30 days (Nifty 500: −0.8%).
- Q1 FY26: Revenue ₹94.0 cr (+12% year on year), EBITDA ₹9.0 cr (+125% year on year), PAT ₹8.0 cr (+60% year on year), EBITDA margin 9.6% (+481 bps). Score 59 of 100, In line with trend. Revenue growth was in line with the company's own trend; EBITDA and profit growth were well above it. EBITDA margin rose 481 bps year on year. Other income 36% of PBT. Revenue fell 30% from last quarter. Share price after the results: +11.7% in 30 days (Nifty 500: +2.4%).
- Q4 FY25: Revenue ₹135 cr (+6% year on year), EBITDA ₹18.0 cr (+13% year on year), PAT ₹15.0 cr (+7% year on year), EBITDA margin 13.3% (+73 bps). Score 36 of 100, Below trend. Revenue, EBITDA and profit growth were below the company's own trend. EBITDA margin rose 73 bps year on year. Profit fell 21% from last quarter. Share price after the results: −3.0% in 29 days (Nifty 500: +0.5%).
- Q3 FY25: Revenue ₹123 cr (+5% year on year), EBITDA ₹24.0 cr (+9% year on year), PAT ₹19.0 cr (+12% year on year), EBITDA margin 19.5% (+71 bps). Score 33 of 100, Below trend. Revenue growth was well below the company's own trend; EBITDA and profit growth were below it. EBITDA margin rose 71 bps year on year.
Past price moves after results do not indicate future moves. Not a recommendation.
Amrutanjan Health Care Limited earnings call, investor presentation and press release summaries
- Q2 FY27: Results deck (3 Nov 2026)
- Q1 FY27: Results deck (11 Aug 2026)
- Q4 FY26: Results deck (8 May 2026)
- Q3 FY26: Results deck (3 Feb 2026)
- Q2 FY26: Results deck (10 Nov 2025)
- Q1 FY26: Results deck (12 Aug 2025)
- Q4 FY25: Results deck (15 May 2025)
Figures from the company's filings with NSE and BSE. Not investment advice.